Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic.

IF 5.7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2025-09-03 DOI:10.1111/dom.70096

Søren Seier, Kine Stamp-Larsen, Simon Birk Kjær Jensen, Signe Sørensen Torekov, Henrik Gudbergsen

{"title":"Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic.","authors":"Søren Seier, Kine Stamp-Larsen, Simon Birk Kjær Jensen, Signe Sørensen Torekov, Henrik Gudbergsen","doi":"10.1111/dom.70096","DOIUrl":null,"url":null,"abstract":"Aims: To evaluate the effectiveness of an online multidisciplinary weight loss service combining individualised semaglutide dosing with intensive behavioural therapy (IBT) in adults living with overweight or obesity.Materials and methods: This retrospective cohort study included data from Danish participants enrolled in a digital weight loss programme via the Embla app between January 2022 and September 2024. The programme offered semaglutide with personalised dosing alongside evidence-based recommendations on nutrition, exercise and habits, delivered through IBT. All data collection and monitoring was conducted via the Embla app. The primary outcome was percentage change in body weight at week 64. Secondary outcomes included semaglutide dose, proportions achieving ≥5%, ≥10%, ≥15%, or ≥20% weight loss, and weight change by baseline BMI and dose.Results: The study included 2694 participants (78% women, mean age 46.8 ± 10.8 years, mean BMI 34.3 ± 4.8). At weeks 26, 52, and 64, the number of participants that remained in the study was: 1580, 712, and 465. Mean weight loss at week 64 was 16.7% (95% CI: -17.4 to -16.0) with a mean semaglutide dose of 1.08 mg/week (SD 0.54). A total of 98% achieved ≥5% and 82% achieved ≥10% weight loss. Weight change was consistent across BMI classes and medication doses.Conclusions: Participants achieved clinically meaningful weight loss comparable to that seen in randomised trials, despite using lower semaglutide doses. These findings support the effectiveness of a personalised, treat-to-target approach integrating medical and behavioural obesity management in a digital setting.Trial registration: https://osf.io/86kmc/.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.70096","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: To evaluate the effectiveness of an online multidisciplinary weight loss service combining individualised semaglutide dosing with intensive behavioural therapy (IBT) in adults living with overweight or obesity.

Materials and methods: This retrospective cohort study included data from Danish participants enrolled in a digital weight loss programme via the Embla app between January 2022 and September 2024. The programme offered semaglutide with personalised dosing alongside evidence-based recommendations on nutrition, exercise and habits, delivered through IBT. All data collection and monitoring was conducted via the Embla app. The primary outcome was percentage change in body weight at week 64. Secondary outcomes included semaglutide dose, proportions achieving ≥5%, ≥10%, ≥15%, or ≥20% weight loss, and weight change by baseline BMI and dose.

Results: The study included 2694 participants (78% women, mean age 46.8 ± 10.8 years, mean BMI 34.3 ± 4.8). At weeks 26, 52, and 64, the number of participants that remained in the study was: 1580, 712, and 465. Mean weight loss at week 64 was 16.7% (95% CI: -17.4 to -16.0) with a mean semaglutide dose of 1.08 mg/week (SD 0.54). A total of 98% achieved ≥5% and 82% achieved ≥10% weight loss. Weight change was consistent across BMI classes and medication doses.

Conclusions: Participants achieved clinically meaningful weight loss comparable to that seen in randomised trials, despite using lower semaglutide doses. These findings support the effectiveness of a personalised, treat-to-target approach integrating medical and behavioural obesity management in a digital setting.

Trial registration: https://osf.io/86kmc/.

查看原文本刊更多论文

用西马鲁肽治疗体重管理目标：来自电子健康诊所的真实世界证据。

目的：评估在线多学科减肥服务结合个性化西马鲁肽剂量与强化行为治疗（IBT）对超重或肥胖成人的有效性。材料和方法：这项回顾性队列研究包括了2022年1月至2024年9月期间通过Embla应用程序参加数字减肥计划的丹麦参与者的数据。该项目提供个性化剂量的西马鲁肽，并通过IBT提供关于营养、运动和习惯的循证建议。所有数据的收集和监测都是通过Embla应用程序进行的。主要结果是第64周体重的百分比变化。次要结局包括西马鲁肽剂量、体重减轻≥5%、≥10%、≥15%或≥20%的比例，以及基线BMI和剂量导致的体重变化。结果：研究纳入2694名参与者（78%为女性，平均年龄46.8±10.8岁，平均BMI 34.3±4.8）。在26周、52周和64周，参与研究的人数分别是：1580人、712人和465人。第64周平均体重减轻16.7% (95% CI: -17.4至-16.0)，平均西马鲁肽剂量为1.08 mg/周（SD 0.54）。98%的患者体重减轻≥5%，82%的患者体重减轻≥10%。体重变化在BMI等级和药物剂量之间是一致的。结论：尽管使用较低剂量的西马鲁肽，受试者获得了与随机试验相当的临床有意义的体重减轻。这些发现支持了在数字环境中整合医疗和行为肥胖管理的个性化、从治疗到目标的方法的有效性。试验注册：https://osf.io/86kmc/。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.